|Bid||493.15 x 800|
|Ask||493.54 x 800|
|Day's range||481.83 - 494.30|
|52-week range||317.06 - 560.92|
|Beta (5Y monthly)||1.17|
|PE ratio (TTM)||62.33|
|Earnings date||02 May 2023 - 08 May 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||525.00|
Here is how Aeterna Zentaris (AEZS) and Idexx Laboratories (IDXX) have performed compared to their sector so far this year.
IDEXX's (IDXX) Q4 revenues are driven by continued benefits from expanding the global premium instrument installed base.
Idexx (IDXX) delivered earnings and revenue surprises of 6.77% and 1.48%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?